obesity drug news today october 21 2025 glp-1 Receptor Agonists – From Evolution to Revolution Study finds 40% of GLP-1
Description
The explosion of GLP-1 media coverage has created confusion about what falls under the GLP-1 umbrella
The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects
It just depends on the season of life and wellness goals at the time
For clinics developing truly integrated medical weight loss programs, a once-weekly GLP-1 analog called ecnoglutide is emerging as the most advanced biased-signaling option yet
Gautron L, Elmquist JK, Williams KW
Taheri H, Malek M, Ismail-Beigi F et al (2020) Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
